HomeBlogConditionsSubstance Use Disorder Inpatient Treatment Denied? How to Appeal
March 1, 2026
🛡️
ClaimBack Editorial Team
Insurance appeal specialists · Regulatory research team · How we verify accuracy

Substance Use Disorder Inpatient Treatment Denied? How to Appeal

Insurance denied inpatient or residential SUD treatment? Learn how ASAM criteria, MHPAEA parity law, Ryan Haight Act, and 42 CFR Part 2 affect your appeal.

Inpatient and residential substance use disorder (SUD) treatment saves lives. When insurance denies coverage for these services, the consequences — relapse, overdose, death — can be permanent. Federal and state law provide powerful tools to challenge these denials. Here is what you need to know.

🛡️
Was your insurance claim denied?
Get a professional appeal letter in 3 minutes — citing real regulations for your country and insurer.
Start My Free Appeal →Free analysis · No login required

Why Insurers Deny SUD Inpatient and Residential Treatment

ASAM level-of-care disputes. The American Society of Addiction Medicine (ASAM) Criteria is the gold standard for SUD level-of-care determination. ASAM evaluates six dimensions: acute intoxication and withdrawal, biomedical conditions and complications, emotional/behavioral conditions, readiness to change, relapse potential, and recovery environment. Insurers often apply their own internal criteria that are more restrictive than ASAM — a Mental Health Parity Act (MHPAEA) Explained" class="auto-link">MHPAEA non-quantitative treatment limitation violation.

Day limit denials. Some plans cap inpatient SUD treatment at 28 or 30 days. Under MHPAEA, day limits on SUD treatment must be comparable to any day limits on analogous inpatient medical benefits. If the plan does not cap inpatient medical admissions at 28 days, it cannot cap SUD inpatient at 28 days.

Step-down pressure. Insurers pressure discharge to residential and then to IOP or outpatient before the patient is clinically ready. For opioid and alcohol use disorders, premature step-down increases overdose mortality risk dramatically — especially in the period immediately following discharge.

Concurrent review denials. Daily concurrent reviews that cut off coverage mid-stay are a particularly aggressive insurer tactic. If the concurrent review criteria are more restrictive than those applied to comparable medical admissions, this is a parity violation.

MHPAEA: The Federal Parity Framework

MHPAEA requires that SUD benefits — including inpatient and residential treatment — not be subject to more restrictive quantitative or non-quantitative treatment limitations than comparable medical or surgical benefits. This is one of the strongest legal protections available for SUD denials.

The comparative analysis requirement under the Consolidated Appropriations Act of 2021 is especially useful. Demand in writing that your insurer provide a MHPAEA comparative analysis. Many insurers cannot produce a compliant analysis, which significantly strengthens your appeal and any subsequent regulatory complaint.

42 CFR Part 2: Confidentiality and Your Appeal

If you are appealing a SUD treatment denial, be aware of federal confidentiality rules under 42 CFR Part 2. Records from federally assisted SUD treatment programs cannot be disclosed without specific patient consent. When gathering records for your appeal, confirm that the treatment facility has the appropriate consent form on file before sharing records with the insurer or insurer's reviewer.

Time-sensitive: appeal deadlines are real.
Most insurers require appeals within 30–180 days of denial. After that, you lose your right to contest. Start your free appeal now →
Fighting a denied claim?
ClaimBack generates a professional appeal letter in 3 minutes — citing real insurance regulations for your country. Get your free analysis →

In practice, you will sign an authorization as part of the appeal process — but understanding Part 2 helps you know what records can be shared and how.

The Ryan Haight Act and Telehealth SUD Treatment

The Ryan Haight Online Pharmacy Consumer Protection Act historically required an in-person evaluation before prescribing controlled substances including buprenorphine via telemedicine. Pandemic-era DEA waivers significantly relaxed these requirements, and ongoing regulatory changes continue to affect telehealth SUD prescribing.

If your SUD treatment was delivered via telehealth and the insurer denied it citing prescribing compliance issues, the regulatory landscape matters. Check the current DEA rules and your state's telehealth prescribing standards, and document compliance explicitly in your appeal.

Building Your SUD Inpatient Appeal

Include:

  • Complete ASAM criteria assessment from the treating clinical team documenting all six dimensions
  • Treating physician's or counselor's letter explaining why inpatient or residential treatment is medically necessary and why a lower level of care is insufficient
  • Documentation of prior treatment attempts at lower levels of care
  • Medical records: vital signs, lab results, withdrawal monitoring documentation
  • Rebuttal of the insurer's specific denial rationale (day limit, step-down, concurrent review)
  • MHPAEA comparative analysis request
  • State SUD parity law citations if applicable

State Protections for SUD Treatment

Many states have enacted SUD-specific insurance protections beyond MHPAEA. Several states prohibit step therapy for SUD medications. Some states require coverage of all ASAM levels of care. California, Connecticut, and New York have particularly strong SUD parity enforcement mechanisms. Identify your state's protections and cite them in your appeal.

Overdose Risk and Expedited Review

If the denial creates an immediate risk of relapse and overdose — particularly for opioid use disorder — document the clinical urgency and request expedited review (72-hour decision). The treating physician's letter should explicitly state the mortality risk associated with denial of inpatient care and why outpatient treatment is not a safe alternative.

Fight Back With ClaimBack

SUD inpatient denials are among the highest-stakes insurance disputes in medicine. ClaimBack helps you build a complete, clinically grounded, legally assertive appeal that puts the insurer on notice of its parity obligations.

Start your SUD inpatient appeal at ClaimBack today.


💰

How much did your insurer deny?

Enter your denied claim amount to see what you could recover.

$
📋
Get the free appeal checklist
The 12-point checklist that helped ~60% of appealed claims get overturned.
Free · No spam · Unsubscribe any time
40–83% of appeals win. Yours could too.

Your insurer is counting on you giving up.

Most people do. Less than 1% of denied claimants ever appeal — even though the majority who do win. ClaimBack was built by people who were denied, who fought back, and who refused to accept "no" from an insurer.

We give you the same appeal arguments that attorneys use — in 3 minutes, for free. Your denial deadline is ticking. Don't let it expire.

Free analysis · No credit card · Takes 3 minutes

More from ClaimBack

ClaimBack helps you fight denied insurance claims with appeal letters built on AI and data from thousands of real denials. Start your free analysis — it takes 3 minutes.